175 related articles for article (PubMed ID: 1568220)
1. Tumor cell kinetics following antineoplastic ether phospholipid treatment.
Principe P; Sidoti C; Braquet P
Cancer Res; 1992 May; 52(9):2509-15. PubMed ID: 1568220
[TBL] [Abstract][Full Text] [Related]
2. Tumor cell kinetics following long-term treatment with antineoplastic ether phospholipids.
Principe P; Sidoti C; Coulomb H; Broquet C; Braquet P
Cancer Detect Prev; 1994; 18(5):393-400. PubMed ID: 7812986
[TBL] [Abstract][Full Text] [Related]
3. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
4. Cytostatic activity of new synthetic anti-tumor aza-alkyllysophospholipids.
Sidoti C; Principe P; Vandamme B; Broquet C; Braquet P
Int J Cancer; 1992 Jul; 51(5):712-7. PubMed ID: 1612779
[TBL] [Abstract][Full Text] [Related]
5. In vitro antiproliferative activity of combinations of ether lipid analogues and DNA-interactive agents against human tumor cells.
Noseda A; Berens ME; White JG; Modest EJ
Cancer Res; 1988 Apr; 48(7):1788-91. PubMed ID: 3349458
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cell division but not nuclear division by 1-O- octadecyl-2-O-methyl-Sn-glycero-3-phosphocholine.
Pushkareva MY; Janoff AS; Mayhew E
Cell Biol Int; 1999; 23(12):817-28. PubMed ID: 10772756
[TBL] [Abstract][Full Text] [Related]
7. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Chabot MC; Wykle RL; Modest EJ; Daniel LW
Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333
[TBL] [Abstract][Full Text] [Related]
8. Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide.
Fujiwara K; Koike H; Ohishi Y; Shirafuji H; Kohno I; Modest EJ; Kataoka S
Anticancer Res; 1997; 17(3C):2159-67. PubMed ID: 9216681
[TBL] [Abstract][Full Text] [Related]
9. Cytokinetic analysis of cell cycle and sub-phases in MOLT-4 cells by cyclin E + A/DNA multiparameter flow cytometry.
Qin J; Tao D; Duan R; Leng Y; Shen M; Zhou H; Feng Y; Gao C; Yu Y; Li QQ; Hu J; Gong J
Oncol Rep; 2002; 9(5):1041-5. PubMed ID: 12168070
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous analysis of cell cycle kinetics at two different DNA ploidy levels based on DNA content and cyclin B measurements.
Gong J; Traganos F; Darzynkiewicz Z
Cancer Res; 1993 Nov; 53(21):5096-9. PubMed ID: 8221643
[TBL] [Abstract][Full Text] [Related]
12. Fate of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET18-OME) in malignant cells, normal cells, and isolated and perfused rat liver.
Magistrelli A; Villa P; Benfenati E; Modest EJ; Salmona M; Tacconi MT
Drug Metab Dispos; 1995 Jan; 23(1):113-8. PubMed ID: 7720513
[TBL] [Abstract][Full Text] [Related]
13. Salvinal, a novel microtubule inhibitor isolated from Salvia miltiorrhizae Bunge (Danshen), with antimitotic activity in multidrug-sensitive and -resistant human tumor cells.
Chang JY; Chang CY; Kuo CC; Chen LT; Wein YS; Kuo YH
Mol Pharmacol; 2004 Jan; 65(1):77-84. PubMed ID: 14722239
[TBL] [Abstract][Full Text] [Related]
14. Effect of cell cycle on the regulation of the cell surface and secreted forms of type I and type II human tumor necrosis factor receptors.
Pocsik E; Mihalik R; Penzes M; Loetscher H; Gallati H; Aggarwal BB
J Cell Biochem; 1995 Nov; 59(3):303-16. PubMed ID: 8567749
[TBL] [Abstract][Full Text] [Related]
15. Caffeine induces S-phase apoptosis in cis-diamminedichloroplatinum-treated cells, whereas cis-diamminedichloroplatinum induces a block in G2/M.
Shinomiya N; Takemura T; Iwamoto K; Rokutanda M
Cytometry; 1997 Apr; 27(4):365-73. PubMed ID: 9098629
[TBL] [Abstract][Full Text] [Related]
16. Maitotoxin, a calcium channel activator, inhibits cell cycle progression through the G1/S and G2/M transitions and prevents CDC2 kinase activation in GH4C1 cells.
Van Dolah FM; Ramsdell JS
J Cell Physiol; 1996 Jan; 166(1):49-56. PubMed ID: 8557775
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
[TBL] [Abstract][Full Text] [Related]
18. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440.
Petersen ES; Kelley EE; Modest EJ; Burns CP
Cancer Res; 1992 Nov; 52(22):6263-9. PubMed ID: 1423272
[TBL] [Abstract][Full Text] [Related]
19. Enantioselective synthesis and antiproliferative properties of an ilmofosine analog, 2'-(trimethylammonio)ethyl 3-(hexadecyloxy)-2-(methoxymethyl)propyl phosphate, on epithelial cancer cell growth.
Bittman R; Byun HS; Reddy KC; Samadder P; Arthur G
J Med Chem; 1997 Apr; 40(9):1391-5. PubMed ID: 9135036
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity and metabolism of alkyl phospholipid analogues in neoplastic cells.
Hoffman DR; Hoffman LH; Snyder F
Cancer Res; 1986 Nov; 46(11):5803-9. PubMed ID: 3756924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
